Gilead, machine learning startup test AI's drug development potential

Andrea Park - Print  | 

Gilead Sciences, the Foster City, Calif.-based biopharmaceutical company, has teamed up with insitro, a machine learning startup in San Francisco, to develop disease treatments using artificial intelligence.

According to a press release, the three-year collaboration will give insitro an initial $15 million to begin creating and analyzing disease models of nonalcoholic steatohepatitis. NASH is a chronic and progressive liver disease that can lead to fibrosis, cirrhosis and liver cancer, and for which there are few approved treatments.

The startup's insitro Human platform will combine AI with human genetics and genomic data to provide insights into the disease's makeup and progression, propose forms of treatment and predict patient responses to those therapies. With that information, Gilead will then chemically develop up to five of the proposed treatments for NASH.

More articles about AI:
AI-driven apps are coaching digital-first millennial managers
Research roadmap details path to incorporating AI into radiology
Intuit CIO shares strategies for successful AI integration

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.